The state of the National Health Service is always a major issue come election time, and the run-up to the UK’s 12 December poll this year is unlikely to be an exception.
The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges that it has yet to make the most of these drugs.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
